Study on Daxdilimab for SLE Treatment Misses Primary Endpoint
A Phase 2 study to evaluate the safety and efficacy of daxdilimab for treatment of active systemic lupus erythematosus (SLE) failed to meet its primary end point and did not obtain a significant difference in disease activity compared to placebo. Daxdilimab is an antibody-based therapy designed to reduce dendritic cells, a type of immune cell in the body.
More than 200 people with SLE were enrolled in the study and had their lupus disease activity and response to the treatment monitored. Study participants were divided into three groups. One group received a 200 mg injection of daxdilimab every four weeks; the second group received 200 mg given every 12 weeks; and the final group received a placebo given every four weeks.
Investigators are assessing the data to evaluate next steps for research. Continue to follow the Lupus Foundation of America for updates on lupus drug development news and clinical trials. Learn more about medications used to treat lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.Subscribe Now